

Drug-Drug Interaction Prediction using Machine Learning Approach: A Review

Swapnali G. Kadoo¹ and Manish T. Wanjari²

¹Assistant Professor, Kamla Nehru Mahavidyalaya, Nagpur, Maharashtra, India

²Assistant Professor, Shivaji Science College, Nagpur, Maharashtra, India

swapni.kadoo@gmail.com¹, mwebwanjari@gmail.com²

Abstract: Drug-Drug Interactions (DDIs) occur when two or more drugs are taken together, resulting in harmful or undesirable effects in the human body. These interactions can reduce the effectiveness of medications, increase the risk of toxicity or even cause serious health problems. Identifying such interactions is essential to protect patient health and ensure successful treatment outcomes. In the past, detecting DDIs relied on manually reviewing medical literature and using static databases such as Drug Bank and KEGG. However, these approaches are slow and not practical given the growing number of approved and experimental drugs. To address these challenges, this paper discussed a machine learning approach that uses various techniques such as Random Forest, SVM classifiers etc. to automatically predict potential DDIs. The DDI prediction uses molecular properties and structural features of drugs to determine whether a pair of drugs is likely to interact. By automating the detection process, the system improves the speed and accuracy of predictions, aiding healthcare providers in making safer medication choices and also compares the different techniques..

Keywords: Drug-Drug Interactions (DDI), Drug Bank (DB), Random Forest (RF), Support Vector Machine (SVM), Machine Learning (ML).

I. INTRODUCTION

Drug-Drug Interaction (DDI) refers to a change in how a drug affects the body when it is taken along with another drug. Drug-drug interactions can cause unexpected effects on the body, such as adverse drug events (ADEs) and the reasons behind these effects are often not well understood [1]. These interactions are a major contributor to illness and death around the world, as they can lead to harmful medical outcomes. They may reduce or stop the effectiveness of a drug, increase the harmful effects of a drug and indirectly affect the success of treatment and how well patients follow their prescribed regimen. The intended effect of a drug can be greatly changed when taken along with another medication. Because of this, it is very important to understand drug-drug interactions (DDIs) in order to avoid unexpected Adverse Drug Events (ADEs) and to make the most of any positive effects when treating diseases. This need has become even more important as the use of multiple drugs for treating diseases has become more common. A study conducted between 2010 and 2011 found that 67% of older Americans were using five or more medications, including prescription drugs, over-the-counter medicines and dietary supplements [2]. One issue is that DDIs are thought to be linked to about 30% of all reported ADEs [3]. Also, ADEs caused by DDIs are a major reason why some drugs are taken off the market. Even though DDIs are very important, it is very difficult to study all possible interactions clinically. This is because testing these interactions requires involving patients who are taking different foods along with their medications, which is time-consuming and expensive [4].

II. METHODOLOGY

The process of Drug-Drug Interaction (DDI) detection is using the following techniques of machine learning.

2.1 Random Forests are technique that build many decision timbers to make predictions. They are known in drug interaction paintings because they properly handle distinctive styles of facts and not over fit without problems. In

Copyright to IJAR SCT

www.ijarsct.co.in



DOI: 10.48175/IJAR SCT-40028



218

prediction of drug–drug interactions, they use information such as drug structure, language similarity and aspect effects. Each tree votes on whether tablets may interact. The very last answer is based totally on the maximum votes. Random forests also inform us which skills count numbers at most. They work properly though noisy or incomplete information. They can detect complex styles while not having masses of tuning. On the basis of literature, the F1 score, a measure of stability precision and recall, recorded a consistently higher cost, thereby validating the model's effectiveness in dealing with large-scale inequality [5]. The model also recorded an ROC-AUC value of over 0.95, which indicates the robustness of the model functionality to distinguish between interacting and non-interacting pairs of medications [6].

2.2 Support vector machines (SVMs) are supervised fads used for class, including drugs drug-drug interaction (DDI) prediction. They really paint with high-dimensional statistics and deal with each easy and complex relationship. SVM classifier drug pairs as interacting or no longer, using capabilities such as structural similarity, aspect results, gene expression and protein expressions. They find a target that separates instructions by the widest margin, which makes it easier to save you over fitting on small datasets. With using kernel strategies such as RBF, SVMs can also research non-linear styles and make them efficient for complex DDI tasks. The RBF (Radial Basis Function) kernel is a popular mathematical function used by SVMs to map complex, non-linear relationships between biological or chemical data features into a higher-dimensional space. This allows the machine learning model to effectively classify or predict how different drugs will interact with one another [7].

2.3 Gradient Boosting Machines (XGBoost, LightGBM) Gradient-boosting machines, such as XGBoost and LightGBM are robust modes used to predict drug-drug interactions (DDIs). Unlike Random Forests, they build trees one after another; solve errors from previous trees, which helps strengthen accuracy. XGBoost is famous because it is fast, makes use of regularization and works nicely with dependent information. It is often used to screen for side effects, medication styles and molecular similarities. LightGBM (Light Gradient Boosting Machine) is created with the help of Microsoft and makes a specialty of pace and saving memory [8]. It is accurate for massive dataset and can handle hundreds of thousands of drug pairs. Both models can use single language, address lack of facts and say which factors you remember most. Their performance depends on adjusting their settings and balances the records because most drug pairs do not have interaction.

2.4 Recurrent neural networks (RNNs) are a type of artificial neural network that processes sequences of information. They can't forget what came here before and see how relationships are linked over time. This helps them to spot styles in how medication is given to patients, especially during dose changes or drugs are taken with exclusive rights. RNNs can learn how those styles may have facet consequences or interaction. Some individual versions, such as LSTM (Long Short Term Memory) or GRU (Gated Recurrent Unit) are better for keeping layers of long period information [9]. They can also be subtle things like dosage length, method of capsule administration, patient data and laboratory effects to increase accuracy. These tools help doctors recognize how drugs paintings together over time, capturing interactions manifesting days or weeks later.

III. COMPARISON OF DIFFERENT TECHNIQUES USED FOR DRUG-DRUG INTERACTION

Drug-Drug Interaction (DDI) prediction can be approached using one-of-a-kind gadget getting to know techniques, with every approach having awesome theoretical strengths and barriers. Random Forest uses a couple of decision trees and combines their outputs, making it appropriate for handling various drug-related capabilities along with molecular shape, similarity statistics and negative-impact data. Support Vector Machine (SVM) classifies drug pairs by identifying a selection boundary that separates interacting and non-interacting tablets. With kernel features together with the Radial Basis Function (RBF), SVM can version non-linear relationships among chemical, structural, organic and genomic capabilities. It can be useful whilst the available dataset is rather restricted but carries high-dimensional functions. Gradient Boosting strategies such as XGBoost and LightGBM assemble decision trees sequentially, with later bushes focusing on errors made with the aid of earlier timber. These methods can capture complex relationships amongst molecular houses, drug traits and interplay-associated features. They also are suitable for processing large



number of datasets and may offer statistics approximately the relative significance of enter functions. Recurrent Neural Networks (RNNs), such as LSTM and GRU architectures, are designed to process sequential statistics. In DDI prediction, they may be carried out to temporal or sequential affected person and medicinal drug information, which include medication histories, modifications in dosage and clinical activities. Overall, those techniques provide exclusive processes to DDI prediction. Random Forest is beneficial for robust ensemble-based category, SVM is appropriate for high-dimensional and non-linear type problems, gradient boosting methods are suitable for complicated and massive-scale feature relationships, and RNN-based tactics are beneficial when sequential or temporal records is important.

IV. CONCLUSION

Drug-Drug Interactions (DDIs) are an essential scientific concern because the concurrent use of medicines can regulate healing outcomes, boom detrimental effects and have an effect on treatment effects. Effective DDI prediction can guide the early identification of doubtlessly interacting drug pairs and decrease the dependence on time-ingesting scientific assessment of every feasible aggregate. Random Forest can deal with diverse and noisy features thru ensemble selection-making, while Support Vector Machine can classify interacting and non-interacting drug pairs the usage of excessive-dimensional and non-linear relationships. Gradient Boosting strategies such as XGBoost and LightGBM can version complex feature relationships and are suitable for large number of datasets.

RNNs, consisting of LSTM and GRU, can additionally capture sequential and temporal styles in remedy and affected person related statistics. The gadget getting to know techniques discussed in this evaluation offer distinct approaches of analysing drug-associated statistics for DDI prediction. Thus, the selection of a DDI prediction approach depends on the nature, high-quality and scale of the available statistics and the characteristics of the interaction patterns being studied. Combining appropriate drug structural, chemical, organic and scientific features with appropriate system mastering techniques can beef up the systematic prediction of capability DDIs. Such procedures can make a contribution to safer medication use, stepped forward treatment making plans and higher identification of potentially harmful drug combinations.

REFERENCES

- [1] Riechelmann, R.P., Del Giglio, A. 2009. Drug interactions in oncology: How common are they? *Ann Oncol.* 20,1907-12.
- [2] Qato, D.M., Wilder, J., Schumm, L.P., Gillet, V., Alexander, G.C. 2016. Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. *JAMA Intern Med* 176,473 482.
- [3] Pirmohamed, M., Orme, M. 1998. *Drug Interactions of Clinical Importance* (Chapman & Hall, London), pp
- [4] Onakpoya, I.J., Heneghan, C.J., Aronson, J.K. 2016. Post marketing withdrawal of 462 medicinal products because of adverse drug reactions: A systematic review of the world literature. *BMC Med* 14, 10.
- [5] Abdelaziz, I., Fokoue, A., Hassanzadeh, O., Zhang, P., & Sadoghi, M. (2017). "Large scale structural and textual similarity- based mining of knowledge graph to predict drug-drug interactions." *Web Semantics: Science, Services and Agents on the World Wide Web*, 2017.
- [6] Bordes, A., Usunier, N., Garcia-Duran, A., Weston, J., & Yakhnenko, O. (2013). "Translating embeddings for modeling multi relational data." *NIPS*, 2013.
- [7] Review Paper Artificial Intelligence in Drug Interaction Prediction, Shivendra Singh, *Int. J. of Pharm. Sci.*, 2025, Vol 3, Issue 5, 2460-2473 |Review.
- [8] Gottlieb, A., Stein, G. Y., Ruppin, E., & Sharan, R. (2012). Predicting novel drug indications with machine learning. *Molecular Systems Biology*, 7, 496.
- [9] Jagannatha, A. N., & Yu, H. (2016). Bidirectional RNN for medical event detection in electronic health records. *NAACL-HLT*, 473–482.

